These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 39343928)

  • 1. Incidence of serious infection among etanercept and infliximab initiators: safety comparison between biosimilars and bio-originators with Canadian population-based data.
    Birck MG; Lukusa L; Choquette D; Boire G; Maksymowych WP; Singh H; Afif W; Bernatsky S
    BMC Rheumatol; 2024 Sep; 8(1):47. PubMed ID: 39343928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
    Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
    RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System.
    Jourdain H; Hoisnard L; Sbidian E; Zureik M
    RMD Open; 2024 Mar; 10(1):. PubMed ID: 38453213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
    Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN
    Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars for the Treatment of Psoriasis: A Systematic Review of Clinical Trials and Observational Studies.
    Phan DB; Elyoussfi S; Stevenson M; Lunt M; Warren RB; Yiu ZZN
    JAMA Dermatol; 2023 Jul; 159(7):763-771. PubMed ID: 37256582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and safety of tumor necrosis factor inhibitors and their biosimilars in patients with rheumatoid arthritis having an insufficient response to methotrexate : A network meta-analysis.
    Ho Lee Y; Gyu Song G
    Z Rheumatol; 2023 Apr; 82(3):248-255. PubMed ID: 34223982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada.
    Fenna J; McCormack D; Kitchen S; Martins D; Gomes T; Tadrous M
    J Manag Care Spec Pharm; 2021 Apr; 27(4):444-452. PubMed ID: 33769851
    [No Abstract]   [Full Text] [Related]  

  • 9. Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany.
    Moorkens E; Barcina Lacosta T; Vulto AG; Schulz M; Gradl G; Enners S; Selke G; Huys I; Simoens S
    Pharmaceuticals (Basel); 2020 Oct; 13(10):. PubMed ID: 33096709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uptake of rheumatology biosimilars in the absence of forced switching.
    Di Giuseppe D; Frisell T; Ernestam S; Forsblad-D'Elia H; Lindqvist E; Lindström U; Sjöwall C; Askling J;
    Expert Opin Biol Ther; 2018 May; 18(5):499-504. PubMed ID: 29633865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients' Understanding and Attitudes Towards Infliximab and Etanercept Biosimilars: Result of a UK Web-Based Survey.
    Aladul MI; Fitzpatrick RW; Chapman SR
    BioDrugs; 2017 Oct; 31(5):439-446. PubMed ID: 28752242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes after anti-tumour necrosis factor originator to biosimilar switching in children and young people with juvenile idiopathic arthritis in the UK: a national cohort study.
    Kearsley-Fleet L; Baildam E; Beresford MW; Douglas S; Foster HE; Southwood TR; Hyrich KL;
    Lancet Rheumatol; 2024 Jul; 6(7):e438-e446. PubMed ID: 38843858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence patterns in naïve and prevalent use of infliximab and its biosimilar.
    Alanaeme CJ; Sarvesh S; Li CY; Bernatsky S; Curtis JR; Yun H
    BMC Rheumatol; 2022 Nov; 6(1):65. PubMed ID: 36316762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden.
    Di Giuseppe D; Lindstrom U; Bower H; Delcoigne B; Frisell T; Chatzidionysiou K; Sjöwall C; Lindqvist E; Askling J
    Rheumatology (Oxford); 2022 Aug; 61(9):3596-3605. PubMed ID: 34919663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project.
    Trifirò G; Isgrò V; Ingrasciotta Y; Ientile V; L'Abbate L; Foti SS; Belleudi V; Poggi F; Fontana A; Moretti U; Lora R; Sabaini A; Senesi I; Sorrentino C; Puzo MR; Padula A; Fusco M; Giordana R; Solfrini V; Puccini A; Rossi P; Del Zotto S; Leoni O; Zanforlini M; Ancona D; Bavaro V; Garau D; Ledda S; Scondotto S; Allotta A; Tuccori M; Gini R; Bucaneve G; Franchini D; Cavazzana A; Biasi V; Spila Alegiani S; Massari M;
    BioDrugs; 2021 Nov; 35(6):749-764. PubMed ID: 34637126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European risk management plans.
    Lepelaars LRA; Renda F; Pani L; Pimpinella G; Leufkens HGM; Trifirò G; Tafuri G; Mantel-Teeuwisse AK; Trotta F
    Br J Clin Pharmacol; 2018 Apr; 84(4):738-763. PubMed ID: 29164665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars for the treatment of psoriasis.
    Puig L; López-Ferrer A
    Expert Opin Biol Ther; 2019 Oct; 19(10):993-1000. PubMed ID: 31237786
    [No Abstract]   [Full Text] [Related]  

  • 18. Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA.
    Kearsley-Fleet L; Rokad A; Tsoi MF; Zhao SS; Lunt M; Watson KD; ; Hyrich KL
    Rheumatology (Oxford); 2023 Dec; 62(12):3849-3857. PubMed ID: 36943379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices.
    Bansback N; Curtis JR; Huang J; He Z; Evans M; Johansson T; Michaud K; Schmajuk G; Liao KP
    ACR Open Rheumatol; 2020 Feb; 2(2):79-83. PubMed ID: 32043831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis.
    Mansell K; Bhimji H; Eurich D; Mansell H
    BMC Health Serv Res; 2019 Nov; 19(1):827. PubMed ID: 31718624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.